Gemini Therapeutics Company

Gemini Therapeutics focuses on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases.
Technology: Rare Genetic Disorders
Industry: Gene therapy
Headquarters: Cambridge, Massachusetts, United States
Founded Date: 1/1/2015
Employees Number: 11-50
Funding Status: IPO
Investors Number: 3
Total Funding: 139500001
Estimated Revenue: Less than $1M
Last Funding Type: Post-IPO Equity

Visit Website
Register and Claim Ownership